JPMorgan Chase & Co. Buys 14,803 Shares of Waldencast plc (NASDAQ:WALD)

JPMorgan Chase & Co. boosted its position in shares of Waldencast plc (NASDAQ:WALDFree Report) by 52.0% in the third quarter, Holdings Channel.com reports. The firm owned 43,250 shares of the company’s stock after acquiring an additional 14,803 shares during the period. JPMorgan Chase & Co.’s holdings in Waldencast were worth $157,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. raised its position in Waldencast by 293.9% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,854 shares of the company’s stock valued at $25,000 after buying an additional 5,114 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Waldencast in the second quarter valued at approximately $37,000. Catalina Capital Group LLC bought a new stake in shares of Waldencast in the third quarter worth $58,000. McAdam LLC acquired a new position in Waldencast during the third quarter worth $62,000. Finally, Cubist Systematic Strategies LLC bought a new position in Waldencast in the second quarter valued at $85,000. Institutional investors and hedge funds own 41.97% of the company’s stock.

Waldencast Stock Performance

NASDAQ:WALD opened at $3.46 on Friday. Waldencast plc has a 12-month low of $2.40 and a 12-month high of $8.35. The stock’s 50 day moving average price is $3.45 and its two-hundred day moving average price is $3.41. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.78 and a current ratio of 1.47.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on WALD. Canaccord Genuity Group started coverage on shares of Waldencast in a research note on Friday, October 25th. They set a “buy” rating and a $5.00 price objective for the company. DA Davidson raised their price target on Waldencast from $7.25 to $7.50 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Canaccord Genuity Group upped their price objective on Waldencast from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, November 22nd. TD Cowen began coverage on shares of Waldencast in a research note on Monday, December 16th. They issued a “hold” rating and a $4.30 target price for the company. Finally, Telsey Advisory Group restated an “outperform” rating and set a $6.00 target price on shares of Waldencast in a report on Monday, November 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Waldencast presently has an average rating of “Moderate Buy” and a consensus target price of $5.76.

Read Our Latest Report on Waldencast

Waldencast Profile

(Free Report)

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.

Further Reading

Want to see what other hedge funds are holding WALD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waldencast plc (NASDAQ:WALDFree Report).

Institutional Ownership by Quarter for Waldencast (NASDAQ:WALD)

Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.